Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GTx
ClinicalTrials.gov Identifier:
NCT00467844
First received: April 30, 2007
Last updated: June 26, 2014
Last verified: June 2014
Results First Received: January 18, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Supportive Care
Condition: Cachexia
Interventions: Drug: GTx-024
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
GTx -024 1 mg
GTx-024 3 mg
3 mg of Placebo Placebo

Participant Flow:   Overall Study
    GTx -024   GTx-024   3 mg of Placebo
STARTED   53   54   52 
COMPLETED   34   34   38 
NOT COMPLETED   19   20   14 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
GTx -024 1 mg
GTx-024 3 mg
3 mg of Placebo Placebo
Total Total of all reporting groups

Baseline Measures
   GTx -024   GTx-024   3 mg of Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 53   54   52   159 
Age 
[Units: Participants]
       
<=18 years   0   0   0   0 
Between 18 and 65 years   25   22   24   71 
>=65 years   28   32   28   88 
Age 
[Units: Years]
Mean (Standard Deviation)
 65.7  (10.03)   66.3  (10.51)   65.6  (8.73)   65.9  (9.74) 
Gender 
[Units: Participants]
       
Female   19   20   17   56 
Male   34   34   35   103 
Region of Enrollment 
[Units: Participants]
       
United States   39   37   36   112 
Argentina   14   17   16   47 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Efficacy of GTx-024 on Total Body Lean Mass.   [ Time Frame: Baseline to Four Months ]

2.  Secondary:   To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.   [ Time Frame: Four Months ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5  

Reporting Groups
  Description
GTx -024 1 mg
GTx-024 3 mg
3 mg of Placebo Placebo

Other Adverse Events
    GTx -024   GTx-024   3 mg of Placebo
Total, other (not including serious) adverse events       
# participants affected / at risk   47/53 (88.68%)   49/54 (90.74%)   46/52 (88.46%) 
Blood and lymphatic system disorders       
anaemia       
# participants affected / at risk   13/53 (24.53%)   7/54 (12.96%)   8/52 (15.38%) 
neutropenia       
# participants affected / at risk   3/53 (5.66%)   5/54 (9.26%)   2/52 (3.85%) 
thrombocytopenia       
# participants affected / at risk   3/53 (5.66%)   5/54 (9.26%)   3/52 (5.77%) 
Gastrointestinal disorders       
abdominal pain       
# participants affected / at risk   2/53 (3.77%)   8/54 (14.81%)   3/52 (5.77%) 
constipation       
# participants affected / at risk   9/53 (16.98%)   6/54 (11.11%)   2/52 (3.85%) 
diarrhoea       
# participants affected / at risk   8/53 (15.09%)   9/54 (16.67%)   7/52 (13.46%) 
vomiting       
# participants affected / at risk   9/53 (16.98%)   4/54 (7.41%)   6/52 (11.54%) 
asthenia       
# participants affected / at risk   1/53 (1.89%)   7/54 (12.96%)   4/52 (7.69%) 
fatigue       
# participants affected / at risk   8/53 (15.09%)   14/54 (25.93%)   11/52 (21.15%) 
Nausea       
# participants affected / at risk   13/53 (24.53%)   6/54 (11.11%)   7/52 (13.46%) 
General disorders       
pyrexia       
# participants affected / at risk   5/53 (9.43%)   8/54 (14.81%)   3/52 (5.77%) 
Infections and infestations       
pneumonia       
# participants affected / at risk   2/53 (3.77%)   4/54 (7.41%)   2/52 (3.85%) 
Investigations       
weight decreased       
# participants affected / at risk   5/53 (9.43%)   8/54 (14.81%)   5/52 (9.62%) 
Metabolism and nutrition disorders       
anorexia       
# participants affected / at risk   5/53 (9.43%)   6/54 (11.11%)   2/52 (3.85%) 
# events   5      2 
dehydration       
# participants affected / at risk   1/53 (1.89%)   7/54 (12.96%)   6/52 (11.54%) 
# events   1   7   6 
Musculoskeletal and connective tissue disorders       
back pain       
# participants affected / at risk   5/53 (9.43%)   1/54 (1.85%)   3/52 (5.77%) 
# events   5   1   4 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)       
malignant neoplasm progression       
# participants affected / at risk   6/53 (11.32%)   8/54 (14.81%)   8/52 (15.38%) 
# events   8   8   9 
Nervous system disorders       
headache       
# participants affected / at risk   3/53 (5.66%)   5/54 (9.26%)   1/52 (1.92%) 
# events   3   7   1 
Respiratory, thoracic and mediastinal disorders       
cough       
# participants affected / at risk   2/53 (3.77%)   9/54 (16.67%)   6/52 (11.54%) 
# events   2   9   6 
dyspnoea       
# participants affected / at risk   7/53 (13.21%)   4/54 (7.41%)   5/52 (9.62%) 
# events   8   6   5 
1 Term from vocabulary, MedDRA (10.0)



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information